PLSM:NASDAQPulsenmore Ltd. Analysis

Pulsenmore Ltd. (PLSM) is trading around $4.89, comfortably above its 20‑day and 50‑day SMAs (≈$3.75 and $3.80) but still below the 200‑day SMA of $4.44, indicating short‑term momentum with a longer‑term lag. The MACD histogram is positive and the signal line is bullish, reinforcing recent upward price pressure. However, the RSI sits at 71, signaling an overbought condition that could invite a corrective pullback. The stock’s support level near $3.31 provides a cushion, while resistance near $7.15 offers a sizable upside target. Volatility is extreme at roughly 95% over the past 30 days, and despite a near‑zero beta, the price swings make the trade risky in the near term.
On the fundamentals side, the company reported full‑year 2025 revenue of $12.5 million, a 374% jump from the prior year, driven by its portable ultrasound devices. Although profitability remains negative (trailing EPS –$0.85, profit margin –39.6%), free cash flow turned positive at $7.7 million, hinting at improving cash generation. The discounted cash‑flow model values the shares at roughly $42, suggesting the market is severely undervaluing the business. Pulsenmore carries no dividend and has a negligible book value per share, so dividend sustainability is not a consideration. The medical‑device sector, while growth‑oriented, is subject to regulatory scrutiny and competitive pressures, adding a medium‑to‑high risk overlay. Being headquartered in Israel introduces moderate geographic risk, but currency exposure is limited as the stock is priced in USD. Overall, the combination of a dramatic revenue surge, a massive DCF gap, and bullish technical signals makes the stock a compelling long‑run buy, though the near‑term overbought momentum and high volatility advise caution.